Cardio Diagnostics Holdings Inc Cash Flow Conversion Efficiency
Cardio Diagnostics Holdings Inc cash flow conversion efficiency. Based on the latest financial reports, Cardio Diagnostics Holdings Inc (CDIO) has a cash flow conversion efficiency ratio of -0.181x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.34 Million) by net assets ($7.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cardio Diagnostics Holdings Inc (2020–2025)
Cash flow conversion efficiency of Cardio Diagnostics Holdings Inc from 2020 to 2025. This chart illustrates how Cardio Diagnostics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Cardio Diagnostics Holdings Inc for real-time trading data and today's change.
Cardio Diagnostics Holdings Inc Cash Flow Conversion Ratio Explained
Cardio Diagnostics Holdings Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cardio Diagnostics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cardio Diagnostics Holdings Inc ranked by their cash flow conversion efficiency. Also see Cardio Diagnostics Holdings Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GIGLIO.COM S.P.A. O.N.
F:5JR0
|
N/A |
|
WF Holding Limited Ordinary Shares
NASDAQ:WFF
|
N/A |
|
PATRYS Ltd
AU:PAB
|
-2.365x |
|
RealTech AG
XETRA:RTC
|
0.171x |
|
Merino & Co. Ltd
AU:MNC
|
-0.297x |
|
Elkop SA
WAR:EKP
|
0.020x |
|
Biofil Chemicals & Pharmaceuticals Limited
NSE:BIOFILCHEM
|
-0.167x |
|
Jackpot Digital Inc
V:JJ
|
0.170x |
Annual Cash Flow Conversion Efficiency for Cardio Diagnostics Holdings Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Cardio Diagnostics Holdings Inc from 2020 to 2025. Review CDIO free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.97 Million | $-5.73 Million | -0.821x | -57.20% |
| 2024-12-31 | $9.56 Million | $-4.99 Million | -0.522x | +72.76% |
| 2023-12-31 | $2.96 Million | $-5.67 Million | -1.917x | -62.02% |
| 2022-12-31 | $4.30 Million | $-5.09 Million | -1.183x | -115.97% |
| 2021-12-31 | $1.07 Million | $-585.29K | -0.548x | -227.92% |
| 2020-12-31 | $60.37K | $25.86K | 0.428x | -- |
About Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart dise… Read more